Rapid detection of gyrA and parC mutations in quinolone-resistant Salmonella enterica using Pyrosequencing® technology

Journal of Microbiological Methods

Volumn 68, Issue 1, 2007, Pages 163-171

  Hopkins, Katie L ^a   Arnold, Catherine ^a   Threlfall, E John ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

gyrA; parC; Pyrosequencing; Quinolone resistance; Salmonella enterica

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE; NALIDIXIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AMINO ACID SUBSTITUTION; AMPLICON; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL GENETICS; BACTERIUM ISOLATE; DEVICE; DNA SEQUENCE; GASTROENTERITIS; GENE AMPLIFICATION; GENE MUTATION; GENE TECHNOLOGY; GYRA GENE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PARC GENE; POINT MUTATION; PRIORITY JOURNAL; SALMONELLA ENTERICA; SALMONELLOSIS; SEROTYPE; SINGLE NUCLEOTIDE POLYMORPHISM;

AMINO ACID SEQUENCE; BASE SEQUENCE; DNA GYRASE; DNA TOPOISOMERASE IV; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; POINT MUTATION; POLYMERASE CHAIN REACTION; SALMONELLA ENTERICA; SALMONELLA INFECTIONS; SEQUENCE ANALYSIS, DNA;

SALMONELLA; SALMONELLA ENTERICA;

EID: 33846018936     PISSN: 01677012     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mimet.2006.07.006     Document Type: Article

References (27)

1. Allen K.J., and Poppe C. Phenotypic and genotypic characterization of food animal isolates of Salmonella with reduced sensitivity to ciprofloxacin. Microbial Drug Resistance 8 (2002) 375-383
2. Baucheron S., Chaslus-Dancla E., and Cloeckaert A. Role of TolC and parC mutation in high-level fluoroquinolone resistance in Salmonella enterica serotype Typhimurium DT204. Journal of Antimicrobial Chemotherapy 53 (2004) 657-659
3. Boswell T.C., Coleman D.J., Purser N.J., and Cobb R.A. Development of quinolone resistance in Salmonella: failure to prevent splenic abscess. Journal of Infection 34 (1997) 86-87
4. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Fifteenth Informational Supplement M100-S15 (2005)
5. Eaves D.J., Liebana E., Woodward M.J., and Piddock L.J. Detection of gyrA mutations in quinolone-resistant Salmonella enterica by denaturing high-performance liquid chromatography. Journal of Clinical Microbiology 40 (2002) 4121-4125
6. Eaves D.J., Randall L., Gray D.T., Buckley A., Woodward M.J., White A.P., and Piddock L.J. Prevalence of mutations within the quinolone resistance-determining region of gyrA, gyrB, parC, and parE and association with antibiotic resistance in quinolone-resistant Salmonella enterica. Antimicrobial Agents and Chemotherapy 48 (2004) 4012-4015
7. Giraud E., Brisabois A., Martel J.L., and Chaslus-Dancla E. Comparative studies of mutations in animal isolates and experimental in vitro- and in vivo-selected mutants of Salmonella spp. suggest a counterselection of highly fluoroquinolone-resistant strains in the field. Antimicrobial Agents and Chemotherapy 43 (1999) 2131-2137
8. Griggs D.J., Gensberg K., and Piddock L.J. Mutations in gyrA gene of quinolone-resistant Salmonella serotypes isolated from humans and animals. Antimicrobial Agents and Chemotherapy 40 (1996) 1009-1013
9. Hansen H., and Heisig P. Topoisomerase IV mutations in quinolone-resistant salmonellae selected in vitro. Microbial Drug Resistance 9 (2003) 25-32
10. Heisig P. High-level fluoroquinolone resistance in a Salmonella typhimurium isolate due to alterations in both gyrA and gyrB genes. Journal of Antimicrobial Chemotherapy 32 (1993) 367-377
11. Heisig P. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrobial Agents and Chemotherapy 40 (1996) 879-885
12. Hopkins K.L., Davies R.H., and Threlfall E.J. Mechanisms of quinolone resistance in Escherichia coli and Salmonella: recent developments. International Journal of Antimicrobial Agents 25 (2005) 358-373
13. Khodursky A.B., Zechiedrich E.L., and Cozzarelli N.R. Topoisomerase IV is a target of quinolones in Escherichia coli. Proceedings of the National Academy of Sciences of the United States of America 92 (1995) 11801-11805
14. Kumagai Y., Kato J.I., Hoshino K., Akasaka T., Sato K., and Ikeda H. Quinolone-resistant mutants of Escherichia coli DNA topoisomerase IV parC gene. Antimicrobial Agents and Chemotherapy 40 (1996) 710-714
15. Liebana E., Clouting C., Cassar C.A., Randall L.P., Walker R.A., Threlfall E.J., Clifton-Hadley F.A., Ridley A.M., and Davies R.H. Comparison of gyrA mutations, cyclohexane resistance, and the presence of class I integrons in Salmonella enterica from farm animals in England and Wales. Journal of Clinical Microbiology 40 (2002) 1481-1486
16. Lindstedt B.A., Aas L., and Kapperud G. Geographically dependent distribution of gyrA gene mutations at codons 83 and 87 in Salmonella hadar, and a novel codon 81 Gly to His mutation in Salmonella enteritidis. APMIS 112 (2004) 165-171
17. Ling J.M., Chan E.W., Lam A.W., and Cheng A.F. Mutations in topoisomerase genes of fluoroquinolone-resistant salmonellae in Hong Kong. Antimicrobial Agents and Chemotherapy 47 (2003) 3567-3573
18. Pers C., Søgaard P., and Pallesen L. Selection of multiple resistance in Salmonella enteritidis during treatment with ciprofloxacin. Scandinavian Journal of Infectious Diseases 28 (1996) 529-531
19. Qiang Y.Z., Qin T., Fu W., Cheng W.P., Li Y.S., and Yi G. Use of a rapid mismatch PCR method to detect gyrA and parC mutations in ciprofloxacin-resistant clinical isolates of Escherichia coli. Journal of Antimicrobial Chemotherapy 49 (2002) 549-552
20. Randall L.P., Coldham N.G., and Woodward M.J. Detection of mutations in Salmonella enterica gyrA, gyrB, parC and parE genes by denaturing high performance liquid chromatography (DHPLC) using standard HPLC instrumentation. Journal of Antimicrobial Chemotherapy 56 (2005) 619-623
21. Reyna F., Huesca M., González V., and Fuchs L.Y. Salmonella typhimurium gyrA mutations associated with fluoroquinolone resistance. Antimicrobial Agents and Chemotherapy 39 (1995) 1621-1623
22. Ronaghi M., Uhlen M., and Nyren P. A sequencing method based on real-time pyrophosphate. Science 281 (1998) 363-365
23. Ruiz J., Castro D., Goñi P., Santamaria J.A., Borrego J.J., and Vila J. Analysis of the mechanism of quinolone resistance in nalidixic acid-resistant clinical isolates of Salmonella serotype Typhimurium. Journal of Medical Microbiology 46 (1997) 623-628
24. Threlfall E.J., Fisher I.S.T., Berghold C., Gerner-Smidt P., Tschäpe H., Cormican M., Luzzi I., Schnieder F., Wannet W., Machado J., and Edwards G. Antimicrobial drug resistance in isolates of Salmonella enterica from cases of salmonellosis in humans in Europe in 2000: results of international multi-centre surveillance. Eurosurveillance 8 (2003) 41-45
25. Vasallo F.J., Martin-Rabadan P., Alcala L., Garcia-Lechuz J.M., Rodriguez-Creixems M., and Bouza E. Failure of ciprofloxacin therapy for invasive nontyphoidal salmonellosis. Clinical Infectious Diseases 26 (1998) 535-536
26. Walker R.A., Lawson A.J., Lindsay E.A., Ward L.R., Wright P.A., Bolton F.J., Wareing D.R., Corkish J.D., Davies R.H., and Threlfall E.J. Decreased susceptibility to ciprofloxacin in outbreak-associated multiresistant Salmonella typhimurium DT104. Veterinary Record 147 (2000) 395-396
27. Walker R.A., Saunders N., Lawson A.J., Lindsay E.A., Dassama M., Ward L.R., Woodward M.J., Davies R.H., Liebana E., and Threlfall E.J. Use of a LightCycler gyrA mutation assay for rapid identification of mutations conferring decreased susceptibility to ciprofloxacin in multiresistant Salmonella enterica serotype Typhimurium DT104 isolates. Journal of Clinical Microbiology 39 (2001) 1443-1448